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Abstract
Approximately thirty percent of patients with soft-tissue sarcoma die from pulmonary metastases. 
The mechanisms that drive sarcoma metastasis are not well understood. Recently, we identified 
miR-182 as a driver of sarcoma metastasis in a primary mouse model of soft-tissue sarcoma. We 
also observed elevated miR-182 in a subset of primary human sarcomas that metastasized to the 
lungs. Here, we show that myogenic differentiation factors regulate miR-182 levels to contribute 
to metastasis in mouse models. We find that MyoD directly binds the miR-182 promoter to 
increase miR-182 expression. Furthermore, mechanistic studies revealed that Pax7 can promote 
sarcoma metastasis in vivo through MyoD-dependent regulation of pro-metastatic miR-182. Taken 
together, these results suggest that sarcoma metastasis can be partially controlled through Pax7/
MyoD-dependent activation of miR-182 and provide insight into the role that myogenic 
transcription factors play in sarcoma progression.
Introduction
Approximately ninety percent of all cancer deaths are due to metastatic disease (1). Unlike 
primary tumors, which are often controlled locally with surgery and radiation therapy, 
systemic chemotherapy often fails to eradicate metastases. Many of the somatic mutations 
necessary for metastasis of epithelial tumors are present within distinct subclones of the 
primary tumor which ultimately give rise to distant metastases (2, 3). In some cases, the risk 
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of metastasis correlates with changes in the genomic sequence (4), copy number (5), or gene 
expression (6–10) of the primary tumor. Despite the clinical importance of metastasis, the 
molecular events that confer these metastatic properties are not well-understood. Due to the 
multiple steps involved and the interaction with the stromal environment, it is challenging to 
distinguish which genes are directly responsible for contributing to metastatic growth 
(known as “drivers”) and which genes are elevated as a result of the metastatic process 
(known as “bystanders”). Thus, a current challenge in the field is to identify drivers of 
metastasis, which could serve as biomarkers in primary tumors to risk-stratify patients for 
systemic therapy and serve as potential anti-metastatic targets.
Soft-tissue sarcomas (STS) are malignant tumors of the connective tissue, including muscle, 
fibrous tissue, fat, blood vessels and nerves. These mesenchymal tumors metastasize to the 
lungs in over thirty percent of patients, resulting in a median patient survival of 15 months 
(11). Due to a lack of molecular markers that accurately classify sarcomas for their potential 
to metastasize, at our institution adult patients with most types of soft-tissue sarcoma do not 
routinely receive adjuvant chemotherapy because of its significant side effects and limited 
response rate (approximately 15–20%) (12). Efforts to understand the metastatic process in 
sarcoma are hindered by the heterogeneity and rarity of sarcoma samples; indeed, over 50 
distinct sarcoma subtypes are known. One of the most common types of soft-tissue sarcoma 
diagnosed in adults is Undifferentiated Pleomorphic Sarcoma (UPS, previously known as 
Malignant Fibrous Histiocytoma, MFH). UPS tumors are characterized by complex 
karyotypes reflecting genomic instability and often harbor inactivating mutations in the p53 
tumor-suppressor pathway. Moreover, mutations in oncogenes are also required for 
sarcomagenesis, and mutations associated with Ras pathway signaling have been identified 
in both human and mouse UPS (13). Despite efforts to define gene signatures for distinct 
sarcoma subtypes, little is known concerning the molecular events contributing to sarcoma 
metastasis.
We recently used genetically engineered mice to delete or overexpress miR-182 in primary 
mouse sarcomas. We demonstrated that miR-182 drives sarcoma metastasis through 
regulation of several proteases that contribute to local invasion, thereby increasing 
extravasation into the blood and ultimately lung metastases (14). Others have recently shown 
that miR-182 levels increase ~500 fold during muscle stem cell activation (15). Myogenic 
development in the adult begins in muscle stem cells, called satellite cells, which express the 
Pax family paired domain transcription factors Pax7 and/or Pax3. Activation of quiescent 
satellite cells leads to the expression of the MyoD family myogenic regulatory factors 
(MRFs) Myf5 and MyoD, which drive the expression of genes in myoblasts. Differentiation 
of myoblasts into terminal muscle fibers is regulated by Mrf4 and myogenin. Thus, a 
cascade of myogenic transcription factors are responsible for muscle differentiation (16) and 
could play a role in controlling miR-182 levels. In a series of 88 high grade soft-tissue 
sarcomas originally diagnosed as UPS, tumors with myogenic differentiation (n=26) showed 
a higher metastatic rate than tumors without myogenic differentiation (n=62, p=0.006) (17). 
Based on these data in human UPS, the identification of miR-182 as a driver of sarcoma 
metastasis (14), and the regulation of miR-182 during muscle development (15), we 
hypothesized that myogenic trascription factors might regulate miR-182 to drive metastasis 
in UPS.
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Results
Myogenic transcription factors are enriched in a subset of metastatic mouse sarcomas
To investigate if transcription factors that regulate myogenic differentiation correlate with 
metastasis in primary mouse sarcomas, we used the Cre-LoxP system to generate primary 
soft-tissue sarcomas in mice (18). Sarcomas develop after intramuscular delivery of an 
adenovirus that expresses Cre (Ad-Cre) into compound mutant mice with conditional 
mutations in both oncogenic Kras (LSL-KrasG12D) and mutant p53 (p53flox/flox), which we 
refer to as KP mice. Cre-mediated recombination simultaneously (1) inactivates p53 
function by deleting exons 2 through 10 and (2) activates oncogenic Kras by removing an 
upstream floxed transcription/translation STOP cassette (termed “loxP-STOP-loxP”, or LSL 
cassette). These KP mice form high-grade spindle cell sarcomas at the site of injection that 
resemble undifferentiated pleomorphic sarcoma (UPS) both histologically and by geneset 
enrichment analysis (18, 19). Although the available genomic data suggest that human UPS 
may often arise in the absence of Kras and p53 mutations, in the related soft tissue sarcoma 
rhabdomyosarcoma, where more comprehensive genomic data are available, mutations of 
Ras and p53 commonly occur (20, 21).
This model exhibits many hallmarks of human sarcoma pathogenesis, including the 
development of lung metastases in ~40% of the mice (22, 23). However, the rapid growth of 
the primary tumors necessitates sacrifice of the animal prior to determining the full 
metastatic potential of the tumor. To mimic the development of pulmonary metastases that 
may occur following surgical resection in patients with no adjuvant therapy, we amputated 
the tumors to generate a cohort of metastatically-annotated sarcomas according to the 
schematic described in Figure 1A. After the sarcoma-bearing limb was amputated, mice 
were monitored for up to 6 months for the development of pulmonary metastases. The 
presence or absence of lung metastases was confirmed by histopathological examination of 
hematoxylin and eosin stained sections of lung by a sarcoma pathologist (L.D). With this 
approach, primary sarcomas were unambiguously divided into two phenotypes: metastatic 
(i.e. developed pulmonary metastasis) and non-metastatic (i.e. did not yield any discernible 
lung metastases).
We performed real-time PCR for multiple myogenic transcription factors in a cohort of 30 
primary mouse sarcomas, of which 15 subsequently developed metastases. We examined 
satellite cell markers (Pax7 and Pax3), all four members of the myogenic regulator factor 
family (Myf5, MyoD, Mrf4 and myogenin) and a marker of terminal muscle differentiation, 
myosin (Figure 1B–H). We found that expression of Pax7, Pax3, Myf5, MyoD, myogenin 
and myosin were enriched in a subset of metastatic primary soft-tissue sarcomas from KP 
mice (Figure 1B–G). Although expression of myogenic regulator factor 4 (Mrf4) was 
elevated in metastatic tumors, this was not statistically significant (Figure 1H). 
Immunohistochemical analysis for Pax7 and MyoD confirmed that protein levels for these 
myogenic factors were expressed at higher levels in metastatic primary tumors (n=10) than 
non-metastatic primary tumors (n=10, Figure 1J–M). Next, we examined the miR-182 levels 
in these tumors. We found a striking correlation between expression of myogenic factors and 
miR-182 (Figure 1I). Tumors with high miR-182 expression (shown in green Figure 1I) are 
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also illustrated in red in Figure 1 B–H. These findings suggested that miR-182 levels may be 
partially regulated by a myogenic differentiation program in primary sarcomas. We also 
examined the expression of miR-182, Pax7, and MyoD in lung metastases. Interestingly, the 
expression of miR-182 by RT-PCR was similar in the lung metastasis compared to the 
matched primary tumor, but Pax7/MyoD-positive primary tumors (n=5) did not maintain the 
expression of these factors (Supplemental Figure 1). This suggests that after colonization in 
the lung, there is no selective pressure to maintain expression of myogenic differentiation.
MyoD directly binds to and controls miR-182 expression
To determine if any of the myogenic transcription factors directly regulated miR-182 levels, 
we performed an in silico analysis (Genomatix) of the miR-182 promoter (14). This analysis 
identified several potential binding sites for the myogenic factor MyoD (Figure 2A). 
Chromatin immunoprecipitation (ChIP) demonstrated that MyoD, but not another myogenic 
transcription factor, Pax7, can directly bind the miR-182 promoter at two distinct sites 
(Figure 2B). We used a luciferase reporter assay to determine that MyoD sites 2 and 3 are 
most important for expression from the miR-182 promoter in C2C12 cells (Supplemental 
Figure 2). To determine if MyoD-specific control of miR-182 levels could contribute to 
metastasis, we examined an independent cohort of KP mouse sarcomas (n=18) and found a 
high correlation between miR-182 levels and MyoD protein expression. (Figure 2C). To 
determine if MyoD expression also correlates with metastasis in human sarcomas, we 
examined a cohort of human UPS tumors. Twenty fresh-frozen UPS samples were obtained 
from patients with known metastatic outcome that did not receive prior therapy (n=12 
metastatic, n=8 non metastatic). Using real-time PCR, we determined that MyoD mRNA 
was enriched in a subset of metastatic tumors (n=5/12), while MyoD was expressed at much 
lower levels in non-metastatic samples (Figure 2D), although this difference was not 
statistically-significant. Importantly, the presence of MyoD in only 40% of the metastatic 
tumors supports the view of metastasis as a complex biological process that utilizes a diverse 
array of biological mechanisms, and suggests that alternative or complementary pathways 
may drive metastasis for the other tumors.
In cells derived from primary mouse sarcomas from KP mice (Ctrl), siRNA-mediated 
knockdown of MyoD decreased miR-182 transcript levels (Figure 2E–F and Supplemental 
Figure 3E). Little effect on miR-182 levels was seen following MyoD knockdown in 
sarcoma cells with constitutive expression of miR-182 from the ROSA26 promoter (LSL-
miR-182, Figure 2E–F). To determine if the MyoD-dependent regulation of miR-182 could 
impact metastatic phenotypes, we examined the ability of MyoD expression to influence the 
in vitro migration and invasion of sarcoma cells with endogenous or constitutive expression 
of miR-182 (Figure 2G–H). While knockdown of MyoD blunted migration/invasion in 
control sarcoma cells, overexpression of miR-182 was sufficient to maintain invasion across 
the transwell membrane. Taken together, these results suggest that MyoD-mediated 
regulation of miR-182 can influence metastatic properties in sarcoma.
Pax7 contributes to sarcoma metastasis
To further define the myogenic proteins that may influence pro-metastatic miR-182 
expression, we sought to identify upstream factors that regulate MyoD expression in tumors. 
Dodd et al. Page 4
Oncogene. Author manuscript; available in PMC 2016 May 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
In a subset of primary metastatic tumors, we found elevation of Pax7 and Pax3 (Figure 1B–
C), two factors that are regulators of MyoD expression during embryonic and postnatal 
myogenesis (24). While both Pax7 and Pax3 are genetically upstream of MyoD, a review of 
the literature made Pax7 a more attractive candidate for several reasons. First, Pax7 is 
universally expressed in satellite cells, while Pax3 expression is limited to specific muscle 
groups (25). Second, Pax7 is known to directly bind to and activate the MyoD promoter and 
displays stronger transcriptional activation properties than Pax3 in C2C12 cells (26, 27). 
Third, expression of dominant-negative Pax7 abolishes MyoD expression in satellite cells in 
culture (28). Taken together, this makes Pax7 an attractive candidate for controlling MyoD 
levels in metastatic sarcoma.
We identified a statistically significant correlation between levels of miR-182 and Pax7 
protein in the mouse tumor cohort (Figure 3A). Moreover, in the cohort of human UPS 
tumors, we determined that Pax7 mRNA was enriched in a subset of metastatic tumors 
(n=6/12, Figure 3B). Thus, in this cohort of human UPS tumors, elevated Pax7 expression 
was exclusive to metastatic tumors and correlated with miR-182 expression, making it a 
promising candidate to promote sarcoma metastasis. Of note, there was a trend for elevated 
Pax7 mRNA expression to correlate with high miR-182 expression in the primary tumors, 
but this correlation did not reach statistical significance (p=0.08) in this relatively small 
sample size (Figure 3C).
To determine if Pax7 expression could influence metastatic phenotypes in our mouse model 
similar to MyoD, we overexpressed Pax7 in KP sarcoma cell lines, which induced miR-182 
expression (Figure 3D). As a control, we overexpressed Pax7 in sarcoma cells derived from 
miR-182flox/flox; LSL-KrasG12D; p53flox/flox mice (14) that lack expression of miR-182 (KO 
cells). While Pax7 expression increased miR-182 levels in wild-type sarcoma cells, it was 
unable to induce miR-182 expression in the knockout cell lines (Figure 3D). Of note, Pax7 
increased both migration and invasion properties in wild-type cells, but was unable to 
influence in vitro metastatic phenotypes in miR-182 knockout (Figure 3E–F) or knockdown 
cells (Supplemental Figure 3A–C). In tandem, we knocked down Pax7 in sarcoma cells 
derived from mice with conditional overexpression of miR-182 (14). In these cells, Pax7 
siRNA inhibited migration and invasion of the control cell line, but Pax7 knockdown 
showed minimal effect in cells with constitutive expression of miR-182 (Figure 3G–I). 
Taken together, these results suggest that Pax7-driven expression of miR-182 is sufficient to 
drive metastatic properties in vitro.
Pax7 and MyoD regulate pro-metastatic miR-182 to increase sarcoma metastasis
To further define the relationship between Pax7, MyoD, and miR182 in the metastatic 
sarcoma cohort, we determined that Pax7 and MyoD protein expression exhibited a strong 
degree of correlation in the mouse tumor cohort (Figure 4A). To determine if Pax7 acts 
through MyoD to regulate miR-182, we used siRNA to knockdown MyoD in sarcoma cells 
that overxpressed Pax7 (Figure 4B and Supplemental Figure 3D). While overexpression of 
Pax7 alone was capable of inducing miR-182 expression (Figure 4C, purple bars), siRNA 
knockdown of MyoD prevented Pax7 from elevating miR-182 levels (Figure 4C, yellow 
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bars). Taken together, these results suggest that Pax7-mediated regulation of miR-182 occurs 
through MyoD.
We next tested the role of Pax7 in modulating miR-182 levels, MyoD expression, and 
metastatic phenotypes through siRNA knockdown of Pax7 in two KP sarcoma cell lines. In 
both cell lines, knockdown of Pax7 with two distinct duplexes resulted in decreased 
miR-182 levels (Figure 2D). Knockdown of Pax7 also impaired migration and invasion of 
these cells in a transwell assay (Figure 2E–F). Of note, knockdown of Pax7 resulted in a 
corresponding decrease in MyoD protein levels, while MyoD knockdown did not alter Pax7 
expression (Figures 4D, 2E).
Pax7 can regulate sarcoma metastasis in vivo
To further define the role of Pax7 in miR-182-mediated sarcoma metastasis, we generated 
stable mouse sarcoma cell lines that express either Flag-tagged Pax7 (29) or a Flag-alone 
control vector. We used two cell lines derived from primary sarcomas resulting from Ad-Cre 
injection into mice that were LSL-KrasG12D; p53flox/flox (KP cells) or LSL-KrasG12D; 
Ink4a/Arfflox/flox (KI cells). High levels of Pax7 were detected by qPCR and immunoblot in 
cells expressing Flag-tagged Pax7 (Supplemental Figure 4A). Overexpression of Pax7 did 
not alter the growth kinetics of the cells (Supplemental Figure 4B–D). Both Pax7-expressing 
cell lines showed elevated levels of metastatic phenotypes in vitro, including increased 
invasion/migration in both transwell and wound healing assays (Supplemental Figure 4E–
H). To directly address the contribution of Pax7 to metastatic lung colonization in vivo, we 
injected sarcoma cells expressing either Flag-alone or Flag-tagged Pax7 orthotopically into 
immunocompetent mice. Following amputation of syngeneic orthotopic tumors, mice were 
sacrificed 6 months later, and the area of their lungs containing metastatic colonies was 
calculated from hematoxylin and eosin (H&E) stained slides. Lungs from mice receiving the 
Pax7-expressing cells showed increased metastatic lung area (Supplemental Figure 4I–J). 
Taken together, these data show that Pax7 expression can induce metastatic phenotypes in 
sarcoma cells in vivo.
miR-182 is required for Pax7-mediated metastasis in vivo
To further explore the Pax7/miR182 relationship in metastasis, we performed an orthotopic 
allograft amputation experiment using sarcoma cells that expressed Pax7 or Flag-alone with 
or without an anti-miR-182 sponge (n=9–10 mice per cell line; Figure 5A). The efficacy of 
the miR-182 sponge was assessed by the expression of the miR-182 target Rsu-1 (Figure 
5A) (14). Following injection of cells into the lower left flank of nude mice, tumors were 
amputated at 200–300 mm3. Mice were sacrificed 7 weeks later or when they showed signs 
of pulmonary distress, and the lungs were examined for the presence of metastases. 
Expression of Pax7 greatly decreased the survival of the mice, while increasing the number 
and percent of metastatic lung growths (Figure 5B–E). Reduction of miR-182 levels by the 
anti-182 sponge decreased the Pax7-dependent metastatic phenotype by increasing the 
survival of mice and decreasing the area and number of lung metastases. These results 
suggest a model where Pax7-dependent metastasis requires miR-182 for sarcoma metastasis 
in vivo (Figure 5F).
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Discussion
Currently, over 30% of adult sarcoma patients develop metastatic disease. We previously 
demonstrated that miR-182 can contribute to metastasis in a mouse model of soft-tissue 
sarcoma(14). However, the events controlling miR-182 expression in these tumors remained 
unexplored. In this current study, we describe a novel mechanism where myogenic 
differentiation factors regulate miR-182 expression and contribute to sarcoma metastasis in 
vivo. Using a mouse model of soft-tissue sarcoma, we observed expression of several 
myogenic transcription factors, including Pax7 and MyoD, in primary metastatic mouse 
tumors. Expression of Pax7 and MyoD correlated with miR-182 levels in both mouse and 
human sarcoma samples. Chromatin immunoprecipitation and luciferase assays confirmed 
that MyoD regulates miR-182 expression through direct binding to the miR-182 promoter. 
In vitro analyses showed MyoD directly controls miR-182 expression and metastatic 
phenotypes, while Pax7 requires MyoD for the regulation of miR-182 levels. Using 
orthotopic allografts of cells engineered with an anti-miR-182 sponge, we determined that 
Pax7-expressing cells require miR-182 to drive sarcoma metastasis in vivo. Taken together, 
these data suggests that one pathway to activate miR-182 in metastatic sarcoma is through a 
Pax7/MyoD-dependent mechanism. As the miR-182 promoter contains multiple binding 
sites for other transcription factors, we postulate that miR-182 activation can occur through 
multiple mechanisms, some of which are independent of myogenic factors (Sachdeva et al, 
unpublished results).
Myogenic transcription factors play a critical role in muscle cell development during 
embryogenesis. For example, precursor cells originating in the somites require Pax3 for 
migration to the sites of muscle wall formation. We speculate that sarcoma cells could be 
hijacking this developmental program to activate migratory phenotypes required for 
metastasis. Just as many epithelial cancers utilize the epithelial-to-mesenchymal transition 
(EMT) to express genes that normally control cell motility during embryonic development, 
we postulate that myogenic transcription factors may also provide a metastatic advantage at 
the primary tumor site through increased migration.
This work expands on the observation that expression of myogenic markers in human 
undifferentiated pleomorphic sarcomas correlates with poor patient outcome(17). Our work 
suggests a mechanism for the role of myogenic transcription factors in promoting metastasis 
in UPS. Recent work from other groups suggests this theme can be extended to other 
sarcoma subtypes. In a particularly aggressive subtype of rhabdomyosarcoma, a recurrent 
somatic mutation in MyoD blocks wild-type function (28). Instead of activating canonical 
MyoD targets involved in differentiation, the mutated MyoD binds MYC consensus 
sequences. This switches downstream transcriptional profiles from muscle differentiation 
genes to proliferative targets. In combination with our data in UPS, these findings identify an 
important role for myogenic transcription factors, such as MyoD, in promoting aggressive 
behavior in sarcomas and suggest further investigations of these proteins in other sarcoma 
subtypes.
This work reveals one mechanism by which myogenic transcription factors regulate 
miR-182 to induce pro-metastatic phenotypes in murine systems in vitro and in vivo. 
Dodd et al. Page 7
Oncogene. Author manuscript; available in PMC 2016 May 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Therefore, further evaluating the role of Pax7, MyoD, and miR-182 in human sarcomas has 
the potential to provide information related to metastatic risk. If the analysis of this pathway 
in large, retrospective sarcoma patient cohorts supports this hypothesis, then prospective 
studies could be undertaken to define the prognostic value of this pathway for patients with 
UPS. Thus, our results provide support for future studies investigating the potential 
prognostic value and biological role of myogenic transcription proteins in human soft-tissue 
sarcoma.
Experimental Procedures
Mouse Sarcoma Model
All mouse work was performed in accordance with Duke University Institutional Animal 
Care and Use Committee approved protocols. Tumors were generated by injection of 
Adenovirus–expressing Cre recombinase (Ad-Cre; University of Iowa, Vector core) into the 
lower left leg of p53flox/flox; LSL-KRasG12D compound mutant mice as previously described 
(18). Following amputation, mice were monitored for up to 6 months for development of 
lung metastases.
Quantitative RT-PCR
RNA was isolated from tumors and cells in TRIZOL, and cDNA synthesis was performed 
with iScript (BioRad). Quantitative RT-PCR was performed on an iQ5 instrument (BioRad) 
using the delta-delta Ct method. Primer sequences can be found in Table S1.
Human samples
UPS samples were obtained from MD Anderson under a protocol approved by the Duke 
University and MD Anderson Institutional Review Boards. Frozen tumor samples were 
processed using TRIZOL, and cDNA synthesis was performed with iScript (BioRad). 
Quantitative RT-PCR was performed on an iQ5 instrument (BioRad) using the delta-delta Ct 
method.
Histology and Immunostaining
Antibodies for immunohistochemistry included: Pax7 (a gift from Chen-Min Fan, Carnegie 
Institute), Ki67 (BD Pharmagen), and MyoD (Santa Cruz). All immunostaining was 
perfomed with citrate-based antigen retrieval, and M.O.M. Kits (Vector Labs) were used for 
Pax7 staining.
In vitro studies
The mouse sarcoma cell lines KP and KI were derived from primary sarcomas that 
developed after intra-muscular Ad-Cre injection into a p53 flox/flox; LSL-KrasG12D or 
Ink4a/Arf flox/flox; LSL-KrasG12D mouse, respectively. Mouse sarcoma cells for miR-182 
experiments were described previously (14). Cells were cultured in DMEM + 10% FBS. For 
colony formation studies, cells were seeded at 500/well in a 6-well dish, and the number of 
existing colonies was determined by crystal violet staining after 2 weeks. Each experiment 
was conducted in triplicate, and the experiment was repeated three times. Data shown are 
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representative of one independent experiment. For cell doubling assays, 1,000 cells were 
seeded overnight and the number of cell doublings was counted daily for four days. 
Migration and invasion assays were completed using the Cultrex Cell Invasion Assay, per 
manufacturer’s instructions. Scratch assays were performed on confluent monolayers, with 
images obtained on an Olympus CKX41 microscope and distances quantified in ImagePro. 
Data shown represent the average of three independent experiments. For siRNA studies, 
sarcoma cell lines were transfected with siRNAs against Pax7 or MyoD with Lipofectamine 
(Invitrogen) following the manufacturer’s protocol. The cells were harvested after 36 hrs and 
48 hrs post transfection for RNA and protein analysis, respectively.
In vivo allografts
129/SvJae or athymic female nude mice were injected intramuscularly with 10,000 cells in 
the lower left flank. Mice were randomly picked for which cell line to receive. Following 7–
14 days of growth, tumors were amputated and mice were followed for 6 months. Mice were 
sacrificed when they presented with symptoms of lung metastases, such as labored breathing 
and hunched posture. Investigators were blind to experimental groups when assessing animal 
health. Mice that died prior to lung harvest were excluded from analysis. Following 
sacrifice, lungs were inflated with formalin prior to harvest and H&E stained sections were 
quantified on Image Pro to calculate the percent of lung volume containing metastases. 
Three sections of lung per mouse were examined.
Western blot analysis
Cells were washed once with cold PBS (Sigma) and lysed for 10 minutes on ice with RIPA 
buffer (Sigma). Protein concentration was performed with BCA Protein Concentration 
Assay (Thermo Scientific). MiniProtean TGX gels (BioRad) were transferred to PVDF by 
wet transfer. Antibodies include Histone H3 (Cell Signaling) and others described in these 
methods.
Chromatin Immunoprecipitation (ChIP) Assay
KP cells stably expressing Flag and Pax-7 were seeded at 50% confluence overnight. 
Nuclear proteins bound to the genomic DNA were cross-linked directly in the cell culture 
medium in 1% formaldehyde at room temperature. Chromatin was digested with 
Micrococcal Nuclease for 20 mins at 37° C and incubated with respective antibodies 
overnight. Protein G agarose beads captured the antibody-chromatin complex. DNA was 
separated from beads and eluted using ChiP elution buffer (Cell signaling technology), 
purified with spin columns and quantified using specific PCR primers (see Table S1).
Luciferase Assay
Cells were transfected with different miR-182 promoter constructs with or without MyoD 
plasmid (lentiviral system from System Biosciences). Cells were harvested 36 h after 
transfection. Luciferase assays were performed as previously described (14). Plasmids with 
different miR-182 promoters were cloned into a luciferase vector (Promega). miR-182 
promoter sequences were PCR amplified with high fidelity Taq polymerase enzyme 
(Invitrogen) using mouse genomic DNA as a template. Primer sequences are provided in 
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Table S1. The amplified fragment was cloned into a Pgl3-basic vector at Kpn1 and Xho1 
sites (Cho-Cho Cloning Kit). To mutate the putative MyoD binding sites in the miR-182 
promoter, we adopted a two-step PCR ligation method with two sets of overlapping primers 
(Table S1) that span the new binding site with mutations. The two amplified PCR fragments 
were used as a template for the second PCR using primers Mir-182-pro-5.4 -kpn1 and 
Mir-182-pro-3.1-rev-xho1 and cloned using a similar strategy as described above.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Myogenic transcription factors are enriched in metastatic primary mouse sarcomas
(A) Schematic of amputation strategy to determine metastatic potential of primary mouse 
sarcomas that is used in this study. (B–H) Levels of myogenic transcripts are elevated in a 
subset of metastatic primary sarcomas in the mouse, including Pax7, Pax3, Myf5, MyoD, 
Myogenin and myosin. * = p<0.05 by Mann-Whitney test. (I) Samples (shown in green) 
with elevated pro-metastatic miR-182 are the identical samples with high expression of 
myogenic markers (shown in red). (J–M) Immunohistochemical analysis shows that both 
Pax7 and MyoD are elevated in metastatic primary mouse sarcomas in comparison to non-
metastatic tumors (p=0.023 (Pax7) and p=0.020 (MyoD), both by Fisher exact test).
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Figure 2. MyoD controls expression of the pro-metastatic miR-182
(A) Schematic of miR-182 promoter highlighting potential MyoD binding sites. (B) 
Chromatin immunoprecipitaiton of miR182 promoter demonstrating direct binding of 
MyoD, but not Pax7, to sites 2 and 3. (C) MyoD protein levels correlate with metastasis and 
miR-182 levels in primary mouse sarcomas by Spearman’s correlation. (D) MyoD mRNA 
levels trend towards enrichment in metastatic human UPS tumors (p=0.114 by Mann-
Whitney test). (E–F) siRNA-mediated knockdown of MyoD decreases miR-182 levels in 
mouse sarcoma cell lines with endogenous miR-182 (Ctrl-B), but has no effect in mouse 
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sarcoma cell lines with constitutive overexpression of miR-182 (LSL-182) * = p<0.05, by 
Mann-Whitney test. (G–H) siRNA-mediated knockdown of MyoD decreases migration and 
invasion in cells that express miR-182 from the endogenous miR-182 promoter (Ctrl), but 
the effect of MyoD knockdown on migration and invasion is largely rescued in cells that 
constitutively overexpress miR-182 from the ROSA-26 promoter (LSL-182). * = p<0.05, ** 
= p<0.01, *** = p<0.001 by two-way ANOVA with Bonferroni correction.
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Figure 3. Pax7 activates metastatic phenotypes via miR-182
(A) In primary mouse sarcomas, levels of Pax7 protein and miR-182 correlate with 
metastatic outcome (green circles) by Spearmans correlation. (B) Pax7 expression is 
enriched in a subset of metastatic human UPS samples (p=0.038 by Mann-Whitney test). (C) 
Human primary sarcomas that metastasized and express elevated Pax7 show a trend for 
increased miR-182 expression (pink diamonds) by Spearmans correlation. (D) 
Overexpression of Pax7 in miR-182 wild-type (WT) cells, but not in miR-182 knockout 
(KO) cells, increases miR-182 levels. ** = p<0.01, *** = p<0.001 by two-way ANOVA with 
Bonferroni correction. (E–F) Pax7 overexpression can increase migration and invasion of 
sarcoma cells in miR-182 WT cells, but is unable to increase in vitro metastatic phenotypes 
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in miR-182 KO cells. ** = p<0.01, *** = p<0.001 by two-way ANOVA with Bonferroni 
correction. (G–I) siRNA-mediated knockdown of Pax7 decreases migration and invasion in 
cells that express wild-type miR-182 (Ctrl), but has minimal impact on migration and 
invasion of cells that constitutively overexpress miR-182 (LSL-182). * = p<0.05, ** = 
p<0.01, *** = p<0.001 by two-way ANOVA with Bonferroni correction.
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Figure 4. Pax7, MyoD and miR-182 cooperate to influence metastasis
(A) There is a strong correlation between levels of Pax7 and MyoD in KP mouse sarcomas. 
(B–C) Overexpression of Pax7 alone can increase miR-182 levels. However, overexpression 
of Pax7 in concert with MyoD knockdown is not sufficient to increase miR-182 levels. * = 
p<0.05, ** = p<0.01, *** = p<0.001 by two-way ANOVA with Bonferroni correction. (D) 
Knockdown of Pax7 in KP-2 and KP-3 sarcoma cells decreases MyoD and miR-182 levels * 
= p<0.05 by Mann-Whitney test. (E–F) Knockdown of Pax7 in KP-2 and KP-3 sarcoma 
cells decreases in vitro migration and invasion. * = p<0.05, ** = p<0.01 by Mann-Whitney 
test.
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Figure 5. Pax7 controls sarcoma metastasis in vivo through miR-182
(A) Expression of GFP-tagged Flag or Pax7 in KP cells with or without an anti-182 sponge. 
Note decrease in protein levels of Rsu-1, a miR-182 target (14), in anti-182-expressing cells. 
(B) Metastasis-free survival of animals receiving orthotopic injection of sarcoma cells 
expressing Flag with vector, Flag with anti-miR-182, Pax7 with vector, or Pax7 with anti-
miR-182. (C–E) Following orthotopic injection, Pax7 expression increases metastatic 
phenotypes, including gross lung metastases (C), percent of metastatic lung area (D), and 
number of metastases (E). * = p<0.05 by one-way ANOVA with Bonferroni correction. 
These phenotypes decrease with the anti-182 sponge. (F) Model of a Pax7/MyoD/miR-182 
axis driving sarcoma metastasis.
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